Ascentage Pharma Group International (NASDAQ:AAPG) Reaches New 52-Week Low – Should You Sell?

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG)’s share price hit a new 52-week low during mid-day trading on Thursday . The stock traded as low as $15.01 and last traded at $15.03, with a volume of 7363 shares traded. The stock had previously closed at $15.58.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on AAPG. BTIG Research reaffirmed a “buy” rating and issued a $48.00 target price on shares of Ascentage Pharma Group International in a report on Friday, August 21st. Raymond James Financial reissued a “buy” rating on shares of Ascentage Pharma Group International in a report on Wednesday, June 10th. Finally, B. Riley Financial began coverage on Ascentage Pharma Group International in a research report on Wednesday, June 10th. They issued a “buy” rating and a $45.00 price target on the stock. Two equities research analysts have rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the company’s stock. Based on data from MarketBeat.com, Ascentage Pharma Group International has a consensus rating of “Buy” and an average price target of $46.43.

Ascentage Pharma Group International Stock Performance

The company has a debt-to-equity ratio of 1.09, a current ratio of 1.22 and a quick ratio of 1.18. The business’s 50-day moving average is $17.54 and its two-hundred day moving average is $20.00.

Ascentage Pharma Group International (NASDAQ:AAPG) last announced its quarterly earnings data on Wednesday, August 19th. The company reported ($0.65) EPS for the quarter. The business had revenue of $22.24 million for the quarter. Analysts forecast that Ascentage Pharma Group International – Unsponsored ADR will post -2.42 earnings per share for the current fiscal year.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a biopharmaceutical company focused on discovering and developing therapies that target apoptosis, the natural process of programmed cell death. Its research is directed primarily toward cancer and other serious diseases in which abnormal cell survival contributes to disease progression.

The company’s pipeline includes small-molecule drug candidates designed to inhibit proteins involved in apoptosis regulation, including BCL-2, MDM2 and inhibitor-of-apoptosis proteins.